Pyxis Oncology, Inc. today presented robust preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2025, supporting the unique extracellular linker payload cleaving mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201). MICVO is a first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin (EDB+FN), which is highly expressed in various solid tumor tissues but minimally in healthy adult tissues.
Key findings from the preclinical studies included the identification of gene signatures associated with increased efficacy of MICVO due to greater linker cleavage in PDX models. A mouse analog of MICVO in a syngeneic model demonstrated strong activity of the cytotoxic Auristatin0101 payload and indicated the potential for MICVO monotherapy to drive immunogenic cell death.
The combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone. These preclinical results strongly support MICVO’s unique, three-pronged mechanism of action, reinforcing its potential as both a monotherapy and in combination with an anti-PD-1 therapy for patients with recurrent and metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.